ASCO 2021 Prostate Cancer - Results from #20

Viewing 21-40 of 90 articles

ASCO 2021: Disparities in Prostate Cancer: Are We Making Progress?

ASCO 2021: Does the Treatment Sequence Matter? Resolving the Controversies

ASCO 2021: Ancestral Characterization of the Genomic Landscape, Comprehensive Genomic Profiling Utilization, and Treatment Patterns May Inform Disparities in Advanced Prostate Cancer: A Large-Scale Analysis

ASCO 2021: Association of Increased Intensity of Prostate-Specific Antigen Screening in Younger African American Men With Improved Prostate Cancer Outcomes

ASCO 2021: A Prospective Validation of the Genomic Classifier To Define High-Metastasis Risk in a Subset of African American Men With Early Localized Prostate Cancer: VanDAAM Study

ASCO 2021: Can We Define the Standard of Therapy for First-Line Metastatic Hormone-Sensitive Prostate Cancer? - Discussion

ASCO 2021: SWOG S1216: A Phase III Randomized Trial Comparing ADT Plus TAK-700 With ADT Plus Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer

ASCO 2021: Talazoparib, an Oral PARP Inhibitor for Men With mCRPC and DNA Damage Response Alterations: Detailed Safety Analyses From TALAPRO-1 Trial

ASCO 2021: Evaluation of PSA Progression After Initiation of Enzalutamide or Abiraterone: Real-World Data on mCRPC

ASCO 2021: Pembrolizumab Plus Enzalutamide for Enzalutamide-Resistant mCRPC: Updated Analyses After One Additional Year of Follow-Up From Cohorts 4 and 5 of the KEYNOTE-199 Study

ASCO 2021: Decreased Fracture Rate by Mandating Bone Protecting Agents in the EORTC 1333/PEACEIII Trial Combining Ra223 with Enzalutamide Versus Enzalutamide Alone: An Updated Safety Analysis

ASCO 2021: A Phase 3 Trial with a 2x2 Factorial Design of Abiraterone Acetate plus Prednisone and/or Local Radiotherapy in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC): First Results of PEACE-1

ASCO 2021: CheckMate 9KD Cohort A1 Final Analysis: Nivolumab + Rucaparib for Post-Chemotherapy mCRPC

ASCO 2021: Sabizabulin (VERU-111), an Oral Cytoskeleton Disruptor, To Treat Men With mCRPC Who Failed an Androgen Receptor Targeting Agent

ASCO 2021: First Results from a Randomized Phase II Study of Cabazitaxel vs an Androgen Receptor Targeted Agent in Patients with Poor-Prognosis Castration-Resistant Prostate Cancer

ASCO 2021: Radiographic Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Men with Metastatic Castrate-Resistant Prostate Cancer

ASCO 2021: The National Impact of the COVID-19 Pandemic on U.S. Prostate Cancer Community Care

ASCO 2021: Differences in the Tumor Genomic Landscape Between African Americans (AA) and Caucasians (CA) Advanced Prostate Cancer (aPC) Patients (Pts) by Comprehensive Genomic Profiling (CGP) of Cell-Free DNA (cfDNA)

ASCO 2021: Prostate Cancer: The Case Study of Disparity in Cancer Care

ASCO 2021: VISION Study Results Discussion: Lutetium-177-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

1
2
3
4
5